Sentences with phrase «metastatic lung cancer cells»

Researchers from the University of Portsmouth's Brain Tumour Research Centre of Excellence have identified molecules which are responsible for metastatic lung cancer cells binding to blood vessels in the brain.

Not exact matches

Scientists from Moffitt reported in the Jan. 19 online edition of Cancer Research that nicotine induces the metastatic spread of lung cancer cells by stimulating a protein called beta - arrestiCancer Research that nicotine induces the metastatic spread of lung cancer cells by stimulating a protein called beta - arresticancer cells by stimulating a protein called beta - arrestin - 1.

The abstract title was: Attempt to Validate Drug Repositioning for Metastatic Small Cell Lung Cancer (SCLC) Therapy Identifies Statins Associated with Survival Benefit.?

Patients with metastatic non-small cell lung cancer will always progress after chemotherapy, so most patients go on to be treated with immunotherapy, a type of therapy that uses the body's immune system to fight cancer.

The Chinese trial will enrol patients who have metastatic non-small cell lung cancer and for whom chemotherapy, radiation therapy and other treatments have failed.

One, in which Dr. Weiss was the senior author, highlighted the extended survival of metastatic small cell lung cancer (SCLC) patients who received statins.

Compared to a control (left), epalrestat treatment (right) reduces the number of metastatic tumors (arrowheads) in the lungs of mice injected with human basal - like breast cancer cells.

Combining radiation therapy with chemotherapy for patients with limited metastatic non-small cell lung cancer (NSCLC) may curb disease progression dramatically when compared to NSCLC patients who only receive chemotherapy, according to a new randomized phase II clinical trial reported today at the 59th Annual Meeting of the American Society for Radiation Oncology (ASTRO).

Multiplexed genetic screening for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) gene rearrangements and subsequent biomarker - guided treatment is cost - effective compared with standard chemotherapy treatment without any molecular testing in the metastatic non-small cell lung cancer (NSCLC) setting in the United States.

When William Pao was a medical oncology fellow at Memorial Sloan Kettering Cancer Center (MSKCC) during the early 2000s, treating patients with metastatic non-small cell lung cancer (NSCLC) was rote: Every patient received the same chemotherapy reCancer Center (MSKCC) during the early 2000s, treating patients with metastatic non-small cell lung cancer (NSCLC) was rote: Every patient received the same chemotherapy recancer (NSCLC) was rote: Every patient received the same chemotherapy regimen.

It is only present at low levels in lung cancer cells which are not metastatic and remain within the lung.

Lu's team then cultured the edited cells, increasing their number, and injected them back into the patient, who has metastatic non-small-cell lung cancer.

Among lung cancer patients; suicide SMR was higher in males (SMR = 8.8), Asians (SMR = 13.7), widowed patients (SMR = 11.6), older patients (70 - 75 years; SMR = 12), patients with undifferentiated tumors (SMR 8.6) or small cell lung carcinoma (SCLC) histology (SMR = 11.2), patients presenting with metastatic disease (SMR = 13.9) and in patients who refused to receive surgical treatment (SMR = 13).

In a study appearing in Science Translational Medicine, the researchers report they have effectively and safely employed this stem cell - targeting system in mice to treat metastatic breast cancer that had spread to the lung.

A Phase 2 Study of MM - 121 in Combination with Docetaxel versus Docetaxel Alone in Patients with Heregulin Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer

The FDA granted approval to pembrolizumab (Keytruda), a anti-PD-1 checkpoint inhibitor, for metastatic non-small cell lung cancer patients whose tumors express PD - L1.

Immunotherapy using checkpoint inhibitors has changed the way we treat several aggressive cancers such as melanoma, non-small cell lung and head & neck cancers, among others, with durable responses achieved in the metastatic setting.

The FDA approved Opdivo ® (nivolumab) for the treatment of patients with metastatic squamous non-small cell lung cancer (NSCLC) after prior therapy.

The FDA granted approval to atezolizumab (TECENTRIQ), and anti-PD-L1 checkpoint inhibitor, for patients with metastatic, chemotherapy - resistant non-small cell lung cancer (NSCLC).

For more information regarding Bristol - Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: • Early stage IB - IIIA, operable non-small cell lung cancer, confirmed in tissue • Lung function capacity capable of tolerating the proposed lung surgery • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 - 1 • Available tissue of primary lung tumor Exclusion Criteria: • Presence of locally advanced, inoperable or metastatic disease • Participants with active, known or suspected autoimmune disease • Prior treatment with any drug that targets T cell co-stimulations pathways (such as checkpoint inhibitors) Other protocol defined inclusion / exclusion criteria could alung cancer, confirmed in tissue • Lung function capacity capable of tolerating the proposed lung surgery • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 - 1 • Available tissue of primary lung tumor Exclusion Criteria: • Presence of locally advanced, inoperable or metastatic disease • Participants with active, known or suspected autoimmune disease • Prior treatment with any drug that targets T cell co-stimulations pathways (such as checkpoint inhibitors) Other protocol defined inclusion / exclusion criteria could aLung function capacity capable of tolerating the proposed lung surgery • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 - 1 • Available tissue of primary lung tumor Exclusion Criteria: • Presence of locally advanced, inoperable or metastatic disease • Participants with active, known or suspected autoimmune disease • Prior treatment with any drug that targets T cell co-stimulations pathways (such as checkpoint inhibitors) Other protocol defined inclusion / exclusion criteria could alung surgery • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 - 1 • Available tissue of primary lung tumor Exclusion Criteria: • Presence of locally advanced, inoperable or metastatic disease • Participants with active, known or suspected autoimmune disease • Prior treatment with any drug that targets T cell co-stimulations pathways (such as checkpoint inhibitors) Other protocol defined inclusion / exclusion criteria could alung tumor Exclusion Criteria: • Presence of locally advanced, inoperable or metastatic disease • Participants with active, known or suspected autoimmune disease • Prior treatment with any drug that targets T cell co-stimulations pathways (such as checkpoint inhibitors) Other protocol defined inclusion / exclusion criteria could apply

Inclusion Criteria: • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 • Have histologically or cytologically confirmed advanced or metastatic non-small cell lung cancer (NSCLC)(Stage IIIb or greater) • Measurable disease, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 • Known PD - L1 tumor status as determined by an immunohistochemistry (IHC) assay performed by the central laboratory on tissue obtained at Screening • A woman of childbearing potential must have a negative highly sensitive serum (beta - human chorionic gonadotropin [beta - hCG]-RRB- at Screening within 14 days prior to study drug administration Inclusion Criteria for Crossover: • Participants must have been randomized to Arm A of the study and had radiographic disease progression according to RECIST 1.1 • Participants must have a mandatory biopsy at the time of disease progression according to RECIST 1.1 prior to crossing over.

Cancer Institute research highlights include innovative studies to develop individualized approaches for treatment and prevention of lung cancer; collaboration between medical and materials science researchers to develop treatments for various types of leukemia using nanotechnology to target only cancer cells; and development of novel therapeutics to treat metastatic melanoma using an approach that regulates the processes leading to tumor develoCancer Institute research highlights include innovative studies to develop individualized approaches for treatment and prevention of lung cancer; collaboration between medical and materials science researchers to develop treatments for various types of leukemia using nanotechnology to target only cancer cells; and development of novel therapeutics to treat metastatic melanoma using an approach that regulates the processes leading to tumor develocancer; collaboration between medical and materials science researchers to develop treatments for various types of leukemia using nanotechnology to target only cancer cells; and development of novel therapeutics to treat metastatic melanoma using an approach that regulates the processes leading to tumor develocancer cells; and development of novel therapeutics to treat metastatic melanoma using an approach that regulates the processes leading to tumor development.

Participants are being asked to take part in this study because they have advanced or metastatic non-small cell lung cancer that has recurred or progressed after previous chemotherapy (s) including a platinum - based treatment.

The Program specializes in the treatment of primary head and neck cancers, brain and spine tumors such as squamous cell carcinoma, basal cell cancer, glomus tumor, paragangliomas, acoustic neuromas, salivary gland and mucosal tumors, astrocytomas, oligodendrogliomas, glioblastomas, and hemangioblastomas, and metastatic tumors that may have arisen from elsewhere in the body such as the breast, lung, or prostate.

Merck's cancer drug Keytruda got the nod of U.S. regulators as a first - line drug for treating metastatic non-small cell lung cancer.

In March, the U.S. Food and Drug Administration approved nivolumab for patients with advanced (metastatic) squamous non-small cell lung cancer.

These include imatinib, sold under the brand name Gleevec for chronic myeloid leukemia; gefitinib, sold as Iressa for metastatic non-small cell lung cancer; and sunitinib, marketed as Sutent, for renal cell cancer and gastrointestinal stromal tumors.

The FDA approved two anti-PD-1 antibodies (nivolumab / Bristol - Myers Squibb and pembrolizumab / Merck & Co.) for metastatic melanoma in 2014, and it extended approval to metastatic squamous non-small cell lung cancer earlier this year.

«He's been sick,» I said, because this had been going on for a year, and though nobody gets better from metastatic small - cell lung cancer, he'd been holding his own for months and months.

This drug is indicated in combination with Cisplatin (a chemotherapeutic drug) for the first - line treatment of patients with inoperable, locally advanced, or metastatic non-small cell lung cancer.

Free Term Papers on Lung CancerLung cancer is not a disease in itself but rather a group of diseases where cells are aggressive and metastatic.

It is currently approved for the treatment of a number of different cancers including metastatic colon cancer, and non-small cell lung cancer.